Summit Therapeutics Inc. (SMMT) income statement
NASDAQ · Healthcare · Biotechnology · 265 employees · CEO Robert W. Duggan
- Price
- $16.03 -1.05%
- Market cap
- $12.8B
- Enterprise value
- $12.4B
- Last report
- Q2 '26 filed 2026-07-23
- Next report
- 2026-11-02 EPS est. -$0.28
Income statement
| Income statement | Trend | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | $7.44M | $12.6M | $19.5M | $24.5M | $36.2M | $28.2M | $41M | $39.7M | $152M | $147M | $133M | $158M | |
| General & administrative | $4.97M | $4.45M | $9.08M | $9.13M | $10.9M | $15.3M | $11.5M | $12.1M | $263M | $77.6M | $62.6M | $62.8M | |
| Other operating expenses | $21.3K | -$217K | -$140K | $0 | $0 | $197K | -$164K | $0 | $0 | $0 | $0 | $0 | |
| Operating expenses | $12.4M | $16.8M | $28.4M | $33.6M | $47.2M | $43.7M | $52.4M | $51.7M | $414M | $225M | $195M | $220M | |
| Operating income | -$12.4M | -$16.8M | -$28.4M | -$33.6M | -$47.2M | -$43.7M | -$52.4M | -$51.7M | -$414M | -$225M | -$195M | -$220M | |
| Interest income | $3.29M | $2.49M | $2.38M | $0 | $0 | $0 | $13.5M | $0 | $2.98M | $5.88M | $5.85M | $4.39M | |
| Interest expense | $2.52M | $2.72M | $2.9M | $3.12M | $3.1M | $2.46M | $9K | $0 | $0 | $0 | $0 | $0 | |
| Other non-operating income (gains on investments, FX ...) | -$3.36M | -$2.09M | -$2.62M | -$2.26M | -$11.9M | -$4.04M | -$3.53M | -$3.05M | $1K | -$5.75M | -$5.79M | -$4.8M | |
| Total non-operating income | $848K | -$636K | -$280K | -$859K | -$608K | $1.59M | $3.52M | $3.05M | $1.99M | $5.75M | $5.79M | $4.8M | |
| Income before tax | -$11.6M | -$17.4M | -$28.7M | -$34.5M | -$47.8M | -$42.1M | -$48.9M | -$48.7M | -$412M | -$219M | -$189M | -$216M | |
| Net income | -$11.6M | -$17.4M | -$28.7M | -$34.5M | -$47.8M | -$42.1M | -$48.9M | -$48.7M | -$412M | -$219M | -$189M | -$216M | |
| EPS (basic) | -$0.02 | -$0.03 | -$0.04 | -$0.05 | -$0.07 | -$0.06 | -$0.07 | -$0.07 | -$0.56 | -$0.29 | -$0.24 | -$0.28 | |
| EPS (diluted) | -$0.02 | -$0.03 | -$0.04 | -$0.05 | -$0.07 | -$0.06 | -$0.07 | -$0.07 | -$0.56 | -$0.29 | -$0.24 | -$0.28 | |
| Shares (basic, weighted) | 698M | 698M | 701M | 702M | 671M | 703M | 683M | 699M | 743M | 766M | 775M | 778M | |
| Shares (diluted, weighted) | 698M | 698M | 701M | 702M | 708M | 727M | 738M | 738M | 743M | 766M | 775M | 778M | |
| Depreciation & amortization | $46K | $32K | $605K | $27K | $20K | $20K | $22K | $25K | $37K | $42K | $44K | $46K | |
| EBITDA | -$9.03M | -$14.7M | -$25.2M | -$31.3M | -$35.3M | -$39.6M | -$48.9M | -$48.7M | -$414M | -$219M | -$189M | -$216M |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.38M | $14.2M | $57.1M | $612K | $629K | $1.34M | $583K | $0 | $0 | $0 | |
| Cost of revenue | $61.7K | $97.7K | $24.9K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $2.38M | $14.2M | $56.4M | $612K | $629K | $1.34M | $583K | $0 | $0 | $0 | |
| Research & development | $19M | $29M | $49.1M | $32.8M | $39M | $63.1M | $43M | $455M | $132M | $538M | |
| Sales & marketing | $0 | $0 | $827K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| General & administrative | $8.28M | $11.9M | $16.2M | $9.29M | $14.1M | $17.5M | $22.1M | $23.7M | $48.3M | $557M | |
| Other operating expenses | $0 | -$917K | -$14.4M | -$18.8M | -$13.5M | -$15.5M | -$4.92M | -$786K | -$250K | $0 | |
| Operating expenses | $27.2M | $40M | $51.7M | $23.2M | $39.5M | $65.1M | $60.2M | $478M | $181M | $1.09B | |
| Operating income | -$24.9M | -$25.8M | $5.39M | -$22.6M | -$71.6M | -$63.7M | -$59.6M | -$478M | -$181M | -$1.09B | |
| Interest income | $10K | $10.1K | $5K | $4.34K | $4K | $0 | $1.51M | $10.4M | $13.5M | $15.5M | |
| Interest expense | $1.08M | $0 | $620K | $32.5K | $255K | $208K | $4.4M | $16.5M | $8.69M | $0 | |
| Other non-operating income (gains on investments, FX ...) | $0 | $908K | -$4.31M | $0 | -$628K | $1.58M | -$7M | -$409M | -$12M | -$14.8M | |
| Total non-operating income | -$854K | $1.91M | $3.69M | -$1.33M | $9.37M | -$1.79M | -$5.54M | -$4.14M | $3.74M | $14.8M | |
| Income before tax | -$25.7M | -$23.9M | $9.08M | -$24M | -$62.3M | -$65.5M | -$65.2M | -$482M | -$177M | -$1.08B | |
| Income tax | -$5.42M | -$3.47M | -$1.79M | $29.6K | -$9.58M | $0 | $0 | $0 | $0 | $0 | |
| Net income | -$21.4M | -$20.2M | $10.9M | -$24M | -$38.5M | -$65.5M | -$65.2M | -$482M | -$177M | -$1.08B | |
| EPS (basic) | -$0.35 | -$0.31 | $0.11 | -$0.73 | -$0.55 | -$0.71 | -$0.34 | -$0.78 | -$0.25 | -$1.44 | |
| EPS (diluted) | -$0.35 | -$0.31 | $0.11 | -$0.73 | -$0.56 | -$0.71 | -$0.34 | -$0.78 | -$0.25 | -$1.44 | |
| Shares (basic, weighted) | 61.1M | 65M | 86.1M | 32.7M | 69.3M | 92.2M | 192M | 620M | 714M | 748M | |
| Shares (diluted, weighted) | 61.5M | 65.4M | 86.1M | 32.8M | 69.5M | 92.2M | 193M | 620M | 719M | 748M | |
| Depreciation & amortization | $58.7K | $566K | $1.95M | $1.42M | $2M | $2.46M | $1.26M | $198K | $89K | $146K | |
| EBITDA | -$24.8M | -$26.2M | $11.7M | -$21.2M | -$36.3M | -$62.9M | -$51.4M | -$69.4M | -$168M | -$1.08B |
Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-02